[{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"WPD Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"WP1122","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Moleculin Biotech","amount2":0.10000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ WPD Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Moleculin Biotech \/ WPD Pharmaceuticals"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Annamycin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"WP1220","moa":"p-STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Annamycin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Moleculin Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"WP1122","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Moleculin Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Moleculin Biotech \/ Moleculin Biotech"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"WP1122","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"WP1066","moa":"p-STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Annamycin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Annamycin","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Whole brain radiation therapy","moa":"p-STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Sterling Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Moleculin Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin Biotech \/ Moleculin Biotech"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"WP1096","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"WP1066","moa":"p-STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Rega Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"WP1096","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Rega Institute","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin Biotech \/ Rega Institute"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Radiation therapy","moa":"p-STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Annamycin","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Moleculin Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Moleculin Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin Biotech \/ Moleculin Biotech"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Annamycin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Catalyst Clinical Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Annamycin","moa":"DNA","graph1":"Oncology","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Moleculin Biotech \/ Moleculin","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin Biotech \/ Moleculin"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Agencja Bada\u0144 Medycznych","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Annamycin","moa":"DNA","graph1":"Oncology","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Moleculin Biotech \/ Agencja Bada\u0144 Medycznych","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin Biotech \/ Agencja Bada\u0144 Medycznych"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Annamycin","moa":"DNA","graph1":"Oncology","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"WPD Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Annamycin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ WPD Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ WPD Pharmaceuticals"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"WPD Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Annamycin","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Moleculin Biotech \/ WPD Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ WPD Pharmaceuticals"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"WP1066","moa":"p-STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Annamycin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Annamycin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Annamycin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Annamycin","moa":"DNA","graph1":"Oncology","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"WP1066","moa":"p-STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Annamycin","moa":"Topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"WP1122","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"2-deoxy-D-glucose Prodrug","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moleculin Biotech \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"2-deoxy-d-glucose Prodrug","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"WP1122","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Annamycin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Annamycin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"L-Annamycin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Annamycin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Annamycin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Annamycin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Annamycin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Annamycin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Annamycin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Annamycin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Annamycin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"WP1066","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Annamycin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Annamycin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"WP1066","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Annamycin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Moleculin Biotech","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"14","companyTruncated":"Moleculin Biotech \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Annamycin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Moleculin Biotech","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"14","companyTruncated":"Moleculin Biotech \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Annamycin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Annamycin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Moleculin Biotech \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Moleculin Biotech

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Annamycin is a next-generation anthracycline, which is being evaluated in combination with cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia.

                          Brand Name : AnnAraC

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 12, 2024

                          Lead Product(s) : Annamycin,Cytarabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Annamycin is a next-generation anthracycline, which is being evaluated for the treatment of subjects with Previously Treated Soft-Tissue Sarcomas with Pulmonary Metastases.

                          Brand Name : AnnAraC

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 23, 2024

                          Lead Product(s) : Annamycin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : WP1066 is an orally bioavailable, small molecule inhibitor of signaling transducer and activator 3 (STAT3). It is being evaluated for the treatment of glioblastoma.

                          Brand Name : WP1066

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 09, 2024

                          Lead Product(s) : WP1066

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The proceeds will be used for the clinical development of the company's lead product AnnAraC (annamycin), which is being evaluated in the late-stage studies for the treating acute myeloid leukemia.

                          Brand Name : AnnAraC

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 19, 2024

                          Lead Product(s) : Annamycin,Cytarabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : H.C. Wainwright & Co

                          Deal Size : $16.5 million

                          Deal Type : Public Offering

                          blank

                          05

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The proceeds will be used for the clinical development of the company's lead product AnnAraC (annamycin), which is being evaluated in the late-stage studies for the treating acute myeloid leukemia.

                          Brand Name : AnnAraC

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 16, 2024

                          Lead Product(s) : Annamycin,Cytarabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : H.C. Wainwright & Co

                          Deal Size : $16.5 million

                          Deal Type : Public Offering

                          blank

                          06

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Annamycin is a next-generation anthracycline, which is being evaluated in combination with cytarabine for the treatment of subjects with acute myeloid leukemia.

                          Brand Name : AnnAraC

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 01, 2024

                          Lead Product(s) : Annamycin,Cytarabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Annamycin is a next-generation anthracycline, which is being evaluated in combination with cytarabine for the treatment of subjects with acute myeloid leukemia.

                          Brand Name : AnnAraC

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 10, 2024

                          Lead Product(s) : Annamycin,Cytarabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Annamycin is a next-generation anthracycline, which is being evaluated in combination with cytarabine for the treatment of subjects with acute myeloid leukemia.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 14, 2024

                          Lead Product(s) : Annamycin,Cytarabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : WP1066 is an orally bioavailable, small molecule inhibitor of signaling transducer and activator 3 (STAT3). It is being evaluated for the treatment of glioblastoma.

                          Brand Name : WP1066

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 15, 2024

                          Lead Product(s) : WP1066

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Annamycin is a next-generation anthracycline, which is being evaluated in combination with cytarabine for the treatment of subjects with acute myeloid leukemia.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 18, 2024

                          Lead Product(s) : Annamycin,Cytarabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank